BREAKFAST AND REGISTRATION

Introduction

Charles J. Ryan, MD - Prostate Cancer Foundation

PSMA primer: the background

Robert Flavell, MD, PhD - University of California, San Francisco

Do the differences in PET agents matter?

Wolfgang Fendler, MD - University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany

False positives in PSMA PET

Courtney Lawhn Heath, MD - University of California, San Francisco

Panel discussion

Speaker panel

ProPSMA versus PreRP – value of the prospective literature

Thomas Hope, MD - University of California, San Francisco

Evaluation of the primary tumor with PSMA PET: time impact of the PRIMARY trial

Louise Emmett, MD - St. Vincent's Hospital Sydney, Australia

Incorporating PSMA PET into RT planning: impact on definitive therapy

Nicholas Nickols, MD - University of California, Los Angeles

Panel discussion

Speaker panel

COFFEE BREAK

Role of MDT in BCR: Oligometastatic disease

Amar Kishan, MD - University of California, Los Angeles

Role of PSMA PET in CRPC patients

Wolfgang Fendler - University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany

Panel discussion

Speaker panel

LUNCH BREAK

PSMA PET appropriate use criteria

Michael Morris, MD - Memorial Sloan Kettering Cancer Center

PSMA PET standardized reporting

Matthias Eiber, MD, PhD - Technische Universität München (TUM), Munich, Germany

Trials evaluating the impact of PSMA PET on management and outcomes

Amar Kishan, MD - University of California, Los Angeles

Tumor Board Discussion (PSMA PET)

Thomas Hope, MD - University of California, San Francisco

Jeremie Calais, MD, MSc - University of California, Los Angeles

Johannes Czernin, MD - University of California, Los Angeles

Poster power pitches

BREAKFAST AND REGISTRATION

Treatment Landscape in mCRPC

Matthew Rettig, MD - University of California, Los Angeles

PSMA radioligand therapy: the VISION and TheraP trials

Michael Morris, MD - Memorial Sloan Kettering Cancer Center

PSMA PET selection of patients for PSMA RLT

Jeremie Calais, MD, MSc - University of California, Los Angeles

Michael Morris, MD - Memorial Sloan Kettering Cancer Center

Oliver Sartor, MD - Mayo Clinic

Thomas Hope, MD - University of California, San Francisco

What is the optimal time for PSMA RLT therapy

Oliver Sartor, MD - Mayo Clinic

EnzaP and the role of AR targeted agents

Louise Emmett, MD - St. Vincent's Hospital Sydney, Australia

Panel discussion

Speaker panel

COFFEE BREAK

Imaging response with PSMA RLT

Jeremie Calais, MD, MSc - University of California, Los Angeles

Post-treatment imaging

Louise Emmett, MD - St. Vincent's Hospital Sydney, Australia

The role of quantitative dosimetry

Carlos Uribe, PhD - BC Cancer and The University of British Columbia

Panel discussion

Speaker panel

Tumor Board Discussion (PSMA RLT)

LUNCH BREAK

Workflow considerations from the front desk to nursing including the supportive care idea

Linda Gardner, MSN, RN, VA-BC - University of California, Los Angeles

Amanda Morley, RN, BSN - University of California, San Francisco

Panel discussion

Speaker panel

Therapy resistance and combination treatment

Johannes Czernin, MD - University of California, Los Angeles

Experience with Immunotherapy

Rahul Aggarwal, MD - University of California, San Francisco

New theranostic targets in prostate cancer

Robert Flavell, MD, PhD - University of California, San Francisco

Cocktails/ portfolio of alpha and beta emitters to improve outcomes

Matthias Eiber - Technische Universität München (TUM), Munich, Germany

Role of Ra-223 in the setting of PSMA PET

Oliver Sartor, MD - Mayo Clinic

Round Table Discussion: moderated panel

Speaker panel

Closing Comments

Thomas Hope, MD - University of California, San Francisco

Jeremie Calais, MD, MSc - University of California, Los Angeles

Johannes Czernin, MD - University of California, Los Angeles